JDL(SH:688057) Zheng Quan Shi Bao·2025-12-21 18:07Core Viewpoint - Company plans to invest 30 million yuan in Zhongke Hongtai to acquire a 10% stake, aiming to optimize its industrial structure and explore new growth opportunities in the medical robotics sector [2] Group 1: Investment Details - The investment is based on the positive outlook for the development of medical robotics technology and applications in strategic emerging industries [2] - The investment will enhance the company's risk resistance and cultivate new profit growth points [2] Group 2: Zhongke Hongtai Overview - Zhongke Hongtai specializes in the research, production, and sales of medical robotics technology and systems, being a technology transfer enterprise incubated by the Chinese Academy of Sciences [2] - The founding team has undertaken over 10 major projects, including the first domestic "863 Program" for vascular interventional surgical robots since 2008, establishing itself as a pioneer in the field [2] - The company holds over 100 independent intellectual property rights and has participated in the formulation of 2 industry standards [2] Group 3: Product Advantages - Zhongke Hongtai's multi-channel vascular interventional surgical robot features bionic design, allowing simultaneous rotation and pushing of guidewires, and can operate two guidewires and two balloon/stent catheters simultaneously [3] - The robot includes force feedback functionality and can perform remote surgeries, full-process robotic assistance, and data collection [3] Group 4: Clinical Trials and Future Plans - The product requires clinical trials before market registration, with the first patient enrolled in a clinical trial for the world's first multi-channel fully assisted vascular interventional surgical robot on November 25, 2025 [3] - As of the announcement date, 16 clinical trials have been completed, and the company is accelerating progress [3] Group 5: Company Strategy - The company is an advanced innovative comprehensive service provider for water environment governance and plans to invest in non-listed companies in the health sector, including medical devices and biomanufacturing, to optimize its industrial structure [2][3]